FDA Approved: AZULFIDINE EN-TABS — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

The FDA approved a supplemental application for Azulfidine En-Tabs (sulfasalazine) filed by Pfizer Laboratories Div Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Juvenile Idiopathic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis

Drugs mentioned

• AZULFIDINE EN-TABS (SULFASALAZINE)

Snippet

SUPPL AP for AZULFIDINE EN-TABS (SULFASALAZINE)